Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

333Background: Patients (pts) with VHL disease are at risk of developing benign and malignant tumors, including ccRCC, pancreatic lesions tumors, CNS hemangioblastomas, and retinal lesions. Inactiv...